Vividion Therapeutics has dosed the first subject in a Phase I trial of an oral inhibitor, VVD-159642, aimed at treating ...

Cerevance's solengepras failed to meet its primary endpoint in the ASCEND trial, which sought to evaluate it as a monotherapy ...

AC Immune has reported additional interim safety and positive immunogenicity outcomes from its placebo-controlled Phase II ...

IoT helps to decentralise clinical trials while providing pharmaceutical companies with a higher return on investment.

At the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD), Roche announced topline results ...

Higher doses of the company’s multiple sclerosis drug failed to show additional benefit in slowing rates of disability ...